Abstract:Ovarian cancer (OC) remains the primary cause of mortality among gynecological malignancies, and the identification of reliable molecular biomarkers to prognosticate OC outcomes is yet to be achieved. The gene palmitoyl protein thioesterase 2 (PPT2), which has been sparsely studied in OC, was closely associated with metabolism. This study aimed to determine the association between PPT2 expression, prognosis, immune infiltration, and potential molecular mechanisms in OC. We obtained the RNA-seq and clinical data from The Cancer Genome Atlas (TCGA), The Genotype-Tissue Expression (GTEx) and Gene Expression Omnibus (GEO) databases, then Kaplan-Meier analysis, univariate Cox regression, multivariate Cox regression, nomogram, and calibration were conducted to assess and verify the role of PPT2. Gene set enrichment analysis (GSEA) was used to figure out the closely correlated pathways with PPT2. Overexpression experiment was performed to explore the function of PPT2. Our findings showed that PPT2 mRNA expression was apparent down-regulation in OC tissue compared to normal ovarian tissues in TCGA, GTEx datasets, and GEO datasets. This differential expression was also confirmed in our in-house datasets at both the mRNA and protein levels. Decreased PPT2 expression correlated with lower survival rates in TCGA, several GEO datasets, and our in-house datasets. Multivariate analysis revealed that PPT2 was an independent factor in predicting better outcomes for OC patients in TCGA and GEO. A negative correlation was revealed between immune infiltration and PPT2 expression through Single-sample GSEA (ssGSEA). Additionally, PPT2 was negatively correlated with an up-regulated immune score, stromal score, and estimate score, suggesting that patients with low PPT2 expression might benefit more from immunotherapy. Numerous chemical agents showed lower IC50 in patients with high PPT2 expression. In single-cell RNA sequencing (scRNA-seq) analysis of several OC datasets, we found PPT2 was mainly expressed in endothelial cells. Furthermore, we found that PPT2 inhibited OC cell proliferation in vitro. Our results demonstrated that PPT2 was considered a favorable prognostic biomarker for OC and may be vital in predicting response to immunotherapy and chemotherapy. Further research was needed to fully understand the relationship between PPT2 and immunotherapy efficacy in OC patients.

Prognostic Significance of PTOV1 Expression in Cancers

Overexpression of Prostate Tumor Overexpressed 1 Correlates with Tumor Progression and Predicts Poor Prognosis in Breast Cancer.

Prostate Tumor Overexpressed 1 (Ptov1) Is A Novel Prognostic Marker For Nasopharyngeal Carcinoma Progression And Poor Survival Outcomes

Expression and clinical significance of P16, P15,and VEGF proteins in primary epithelial ovarian carcinoma

PTOV1 facilitates colorectal cancer cell proliferation through activating AKT1 signaling pathway

Depleting PTOV1 sensitizes non-small cell lung cancer cells to chemotherapy through attenuating cancer stem cell traits

Prostate tumor overexpressed-1, in conjunction with human papillomavirus status, predicts outcome in early-stage human laryngeal squamous cell carcinoma.

Prognostic Value of Long Non-Coding RNA PVT1 As a Novel Biomarker in Various Cancers: a Meta-Analysis.

Prognostic Significance of LncRNA PVT1 and Its Potential Target Gene Network in Human Cancers: a Comprehensive Inquiry Based Upon 21 Cancer Types and 9972 Cases.

Long Noncoding RNA PVT1 As a Potent Predictor of Prognosis in Cancers: a Meta-Analysis.

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

Association Between the Overexpression of PBOV1 and the Prognosis of Patients with Hepatocellular Carcinoma

Pvt1 Expression Is A Predictor For Poor Survival Of Prostate Cancer Patients

Lncrna PVT1 Identified As an Independent Biomarker for Prognosis Surveillance of Solid Tumors Based on Transcriptome Data and Meta-Analysis

Prostate tumour overexpressed-1 promotes tumourigenicity in human breast cancer via activation of Wnt/β-catenin signalling.

The Role of PTP1B (PTPN1) in the Prognosis of Solid Tumors: A Meta-Analysis

Investigating PPT2's role in ovarian cancer prognosis and immunotherapy outcomes

Prognostic Value of Podoplanin in Various Tumors

PTPRO-related CD8(+) T-cell signatures predict prognosis and immunotherapy response in patients with breast cancer

Exploration of PVT1 as a biomarker in prostate cancer

Clinicopathological and Prognostic Significance of Osteopontin Expression in Patients with Prostate Cancer: a Systematic Review and Meta-Analysis